Kentucky Halts Six Compounded Peptides Under State Rules

Kentucky patients and prescribers should expect no compounding of six peptides in state, with no transition period.

Updated on Nov. 22, 2026 in Health

Isometric editorial illustration of plain amber vials and a brass mortar on a stainless bench behind a closed steel barrier, evoking a state compounding restriction.
The Kentucky Board of Pharmacy voted November 18 to decline federal enforcement discretion, barring in-state pharmacies from compounding six peptides, including BPC-157 and TB-500. AI Illustration. Upload story photo >

The Kentucky Board of Pharmacy voted on November 18, 2026 to decline federal enforcement discretion for six peptide bulk drug substances, meaning pharmacies in the state will not compound them under the state's rules. Patients and prescribers who rely on compounded peptides in Kentucky are directly affected by the change.

Why it matters

The Board concluded that none of the six peptides meets Kentucky's compounding requirements, and that a federal interim policy does not change their eligibility under state law. The Board cited unresolved safety concerns and insufficient scientific evidence, which is why it denied waivers and acted without a grace period.

This is a regulatory decision rather than a clinical study, and the Board's stated basis is unresolved safety concerns and insufficient scientific evidence for the six peptides. The Board did not publish new trial data in the source material, so the evidence base for these substances remains the subject of ongoing scientific review.

The players

Kentucky Board of Pharmacy

The state body that licenses and regulates pharmacies and pharmacists in Kentucky, including the rules governing compounded medications.

U.S. Department of Health and Human Services

The federal department whose agencies, including the FDA, oversee drug safety and the compounding policies that govern pharmacies nationwide.

The details

Under Kentucky regulation 201 KAR 2:076, compounded preparations must meet specific state requirements, and the Board found none of the six peptides does. Pharmacies in the state are directed to refrain from compounding, dispensing or shipping preparations containing BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c in or into Kentucky, including by nonresident pharmacies. Violations may be treated as unprofessional conduct and lead to disciplinary action.

Timeline

  1. November 18, 2026: The Board voted to decline compounding waivers for the six peptides.

  2. November 19, 2026: The Board issued a compliance alert confirming it will not extend federal enforcement discretion.

Health Landscape

Compounding pharmacies operate under a patchwork of federal Section 503A provisions and state pharmacy rules, so states can and do diverge on which substances are permitted. Kentucky's action shows how a state can hold a stricter line than the federal interim policy while FDA's bulks list remains under review.

If you or a family member have been receiving a compounded peptide from a Kentucky pharmacy, it is worth asking your prescriber and pharmacist how this change affects your care. Do not stop or change any treatment on your own; bring questions to your physician so any alternatives can be discussed.

The takeaway

State boards can hold compounding standards that differ from federal interim policy, so the rules that apply to your pharmacy depend partly on where you live. Ask your pharmacist which state rules govern any compounded medication you receive.

What happens next

The Board says it will continue monitoring federal developments, including possible additions to FDA's Section 503A bulks list, which could affect the status of these substances.

Further reading

For broader context on how drug safety rules shape what medicines reach patients, browse our Health — General coverage.

Source note: This article includes information reported by The National Law Review - A Free To Use Nationwide Database of Legal Publications.